ReviewClinical and vaccine immunology : CVI2015
Tuberculosis vaccine types and timings.
Review in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.Clinical microbiology reviews · 2023Review
- Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis.Molecular diversity · 2023Article
- Vaccines against Tuberculosis: Where Are We Now?Vaccines · 2023Review
- Principles in Immunology for the Design and Development of Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Cyclic-di-AMP Phosphodiesterase Elicits Protective Immune Responses AgainstFrontiers in cellular and infection microbiology · 2022Article
- Particulate Mycobacterial Vaccines Induce Protective Immunity against Tuberculosis in Mice.Nanomaterials (Basel, Switzerland) · 2021Article
- Variances in BCG protection against COVID-19 mortality: A global assessment.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models.Disease models & mechanisms · 2020Review
- Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks.Scientific reports · 2020Article
- Structural characterization of glycinamide-RNase-transformylase T fromEmerging microbes & infections · 2020Article
- Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.Frontiers in immunology · 2020Review
- Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.Frontiers in immunology · 2020Review
- Cell Differentiation Degree as a Factor Determining the Role for Different T-Helper Populations in Tuberculosis Protection.Frontiers in immunology · 2019Review
- Current trends in tuberculosis vaccine.Medical journal, Armed Forces India · 2019Review
- Evaluation of EZplex MTBC/NTM Real-Time PCR kit: diagnostic accuracy and efficacy in vaccination.Clinical and experimental vaccine research · 2018Article
- Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity toFrontiers in immunology · 2018Review
- Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.Frontiers in immunology · 2018Review
- GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.Clinical and vaccine immunology : CVI · 2017Article
- A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model.Scientific reports · 2017Article
- Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.Human vaccines & immunotherapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, the design of new vaccines directed against Mycobacterium tuberculosis, the most successful bacterial pathogen on the planet, has focused on prophylactic candidates that would be given to individuals while they are still young. It is becoming more apparent, however, that there are several types of vaccine candidates now under development that could be used under various conditions. Thus, in addition to prophylactic vaccines, such as recombinant Mycobacterium bovis BCG or BCG-boosting vaccines, other applications include vaccines that could prevent infection, vaccines that could be given in emergency situations as postexposure vaccines, vaccines that could be used to facilitate chemotherapy, and vaccines that could be used to reduce or prevent relapse and reactivation disease. These approaches are discussed here, including the type of immunity we are trying to specifically target, as well as the limitations of these approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.